Other widely-used insulin brands at that price include Novo Nordisk’s Novolog and Sanofi’s Lantus. Amazon said its website will estimate the consumer’s insurance price.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Insulin prices charged by the three major drug manufacturers spiked over the past two decades. From 2002 through 2013, the average price of insulin nearly tripled, according to the American ...

Health policy experts say Eli Lilly's competitors—Sanofi, which makes Apidra and Lantus, and Novo Nordisk, which makes NovoLog and Levemir—are now facing increasing pressure to respond.

French pharmaceutical company Sanofi, one of the top three insulin manufacturers for the U.S., announced on Thursday it would be cutting the list price for its most prescribed insulin product Lantu… ...

In the lawsuit, Sanofi, which manufactures Lantus (insulin glargine), cites seven patents held from 2009 through 2014, which secure the company’s hold on Lantus, the global leader in insulin.

The insulin market wasn’t nearly as lucrative as it is today. In 1999, for example, Eli Lilly sold $701 million worth of insulin in the U.S., ... Sanofi, which manufactures Lantus, ...

The company makes $15 million every day selling this type of insulin. As shown in a new report from I-MAK, the organization I help direct, the price of Lantus jumped 18 percent each year from 2012 ...

Although insulin has been used as medication for roughly a century, no generic versions of the drug are available. Only three manufacturers — Eli Lilly, Novo Nordisk and Sanofi — control 99% ...